摘要
慢性乙型肝炎 (HBsAg+ ,HBeAg+ ,HBV -DNA+ ) 136例 ,随机分为 3组 ,第 1组 49例采用抗乙肝iRNA2mg隔日肌注 ,3个月 ,联合单磷酸阿糖腺苷 (ArA -AMP) 10mg/kg肌注 5天后 5mg/kg 2 3天 ,胸腺肽 10mg每日肌注30天。第 2组 45例用胸腺肽 90天 ,剂量和其他联合用药同 1组。第 3组 42例为对照组。治疗结束 (3个月 ) 3个组ALT复常率分别为 93 8% ,93 3% ,47 6 % ;HBeAg转阴率 32 7% ,37 8% ,9 4%HBV -DNA转阴率 34 0 % ,40 0 % ,2 4%。停药后随访一年 ,ALT复常率分别为 85 7% ,91 0 % ,5 0 0 %。HBeAg转阴率 30 6 % ,33 3% ,11 9%。HBV -DNA转阴率 30 6 % ,35 6 % ,11 9%。第 1、2两组各项与对照组比全部P <0 0 5 ,第 1与 2组各项目比P >0 0 5。
WT5”BZ]To evaluate effects of HBsAg-iRNA and Ara-AMP combined with thymus peptide therapy of chronic hepatitis B,this was randomized trial 136 patients(HBeAg and HBV-DNA positive)were randomized into three groups,group 1 was deected with HBsAg-iRNA 2mg IM q o d 3 months,Ara-AMP 10mg/Kg,IM q d for 5 days then 5kg/Kg IM q d for 23 days and combined with thyus peptide 10 mg IM q d for 30 days Group 2 thedrugs and dosage same to group 1,but the thymus peptide IM for 90 days Group 3was control by The end of therapy (3MO),those group 1,2,3 the ALT turn to recover (93 85%;93 35%;47 6%),P<0 05,HBeAg turn to negative(32 7%;37 8%;9 4%),HBV-DNA turn to negative(34 0%;40 0%;2 4%),P<0 05 Follow up for one year Those group 1,2,3,ALT turn to recover(85 7%;91 0%;50 0%),P<0 05 HBeAg turn to negative(30 6%;33 3%;11 9%),P<0 05 HBV-DNA turn to negative(30 6%;35 6%;11 9%),P<0 05 Combined with these three drags to treatment chronic hepatitis B are effective [WT5”HZ]
出处
《临床肝胆病杂志》
北大核心
2000年第2期110-111,共2页
Journal of Clinical Hepatology
